Literature DB >> 22070611

Refractoriness in bipolar disorder: definitions and evidence-based treatment.

Konstantinos N Fountoulakis1.   

Abstract

Defining refractoriness in bipolar disorder is complex and should concern and include either every phase and pole or the disorder as a whole. The data on the treatment of refractory bipolar patients are sparse. Combination and add-on studies suggest that in acutely manic patients partial responders to lithium, valproate, or carbamazepine, a good strategy would be to add haloperidol, risperidone, olanzapine, quetiapine, or aripiprazole. Adding oxcarbazepine to lithium is also a choice. There are no reliable data concerning the treatment of refractory bipolar depressives and also there is no compelling data for the maintenance treatment of refractory patients. It seems that patients stabilized on combination treatment might do worse if shifted from combination. Conclusively there are only limited and sometimes confusing data on the treatment of refractory bipolar patients. Further focused research is necessary on this group of patients.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22070611      PMCID: PMC6493614          DOI: 10.1111/j.1755-5949.2011.00259.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  8 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 2.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

3.  Ketamine for Bipolar Depression: Biochemical, Psychotherapeutic, and Psychedelic Approaches.

Authors:  Raquel Bennett; Christian Yavorsky; Gary Bravo
Journal:  Front Psychiatry       Date:  2022-05-23       Impact factor: 5.435

4.  Bupropion Maintenance Treatment in Refractory Bipolar Depression: A Case Report.

Authors:  Julia Dehning; Heinz Grunze; Armand Hausmann
Journal:  Clin Pract Epidemiol Ment Health       Date:  2017-05-31

5.  Does the "Silver Bullet" Lose its Shine Over the Time? Assessment of Loss of Lithium Response in a Preliminary Sample of Bipolar Disorder Outpatients.

Authors:  M Fornaro; B Stubbs; D De Berardis; F Iasevoli; M Solmi; N Veronese; A Carano; G Perna; A De Bartolomeis
Journal:  Clin Pract Epidemiol Ment Health       Date:  2016-12-23

Review 6.  The Impact of Subsyndromal Bipolar Symptoms on Patient's Functionality and Quality of Life.

Authors:  Heinz Grunze; Christoph Born
Journal:  Front Psychiatry       Date:  2020-06-12       Impact factor: 4.157

7.  The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder.

Authors:  Konstantinos N Fountoulakis; Lakshmi N Yatham; Heinz Grunze; Eduard Vieta; Allan H Young; Pierre Blier; Mauricio Tohen; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2020-04-23       Impact factor: 5.176

8.  Aripiprazole in the treatment of refractory mood disorders: a case series.

Authors:  Ather Muneer
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-08-12       Impact factor: 2.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.